Second- and third-generation beta-blocking drugs in chronic heart failure

Michael R. Bristow, William T. Abraham, Tsutomu Yoshikawa, Michel White, Brack G. Hattler, Thomas S. Crisman, Brian D. Lowes, A. D. Robertson, Patti Larrabee, Edward M. Gilbert

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The left-ventricular (LV) functional, hemodynamic, and antiadrenergic effects of metoprolol, bucindolol, and carvedilol have been compared in three concurrent placebo-controlled clinical trials in patients with symptomatic idiopathic dilated cardiomyopathy. All three drugs were well tolerated, all produced at least moderate degrees of β-blockade as assessed by reduction in exercise heart rate, and all increased the left-ventricular ejection fraction. Compared with the β1-selective, second-generation compound metoprolol, the third-generation compounds bucindolol and carvedilol lowered indices of adrenergic activity and tended to improve LV function to a greater extent. In patients with chronic heart failure there may be important therapeutic response differences between second- and third-generation beta-blocking agents.

Original languageEnglish (US)
Pages (from-to)291-296
Number of pages6
JournalCardiovascular Drugs and Therapy
Volume11
Issue numberSUPPL. 1
DOIs
StatePublished - Jun 12 1997

Fingerprint

Metoprolol
Heart Failure
Adrenergic Antagonists
Controlled Clinical Trials
Dilated Cardiomyopathy
Left Ventricular Function
Pharmaceutical Preparations
Stroke Volume
Adrenergic Agents
Heart Rate
Hemodynamics
Placebos
Exercise
bucindolol
carvedilol
Therapeutics

Keywords

  • Antiadrenergic activity
  • Beta-blocking drugs
  • Chronic heart failure
  • Exercise response
  • Idiopathic dilated cardiomyopathy
  • Ischemic cardiomyopathy
  • Left ventricular function

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

Bristow, M. R., Abraham, W. T., Yoshikawa, T., White, M., Hattler, B. G., Crisman, T. S., ... Gilbert, E. M. (1997). Second- and third-generation beta-blocking drugs in chronic heart failure. Cardiovascular Drugs and Therapy, 11(SUPPL. 1), 291-296. https://doi.org/10.1023/A:1007748131847

Second- and third-generation beta-blocking drugs in chronic heart failure. / Bristow, Michael R.; Abraham, William T.; Yoshikawa, Tsutomu; White, Michel; Hattler, Brack G.; Crisman, Thomas S.; Lowes, Brian D.; Robertson, A. D.; Larrabee, Patti; Gilbert, Edward M.

In: Cardiovascular Drugs and Therapy, Vol. 11, No. SUPPL. 1, 12.06.1997, p. 291-296.

Research output: Contribution to journalArticle

Bristow, MR, Abraham, WT, Yoshikawa, T, White, M, Hattler, BG, Crisman, TS, Lowes, BD, Robertson, AD, Larrabee, P & Gilbert, EM 1997, 'Second- and third-generation beta-blocking drugs in chronic heart failure', Cardiovascular Drugs and Therapy, vol. 11, no. SUPPL. 1, pp. 291-296. https://doi.org/10.1023/A:1007748131847
Bristow MR, Abraham WT, Yoshikawa T, White M, Hattler BG, Crisman TS et al. Second- and third-generation beta-blocking drugs in chronic heart failure. Cardiovascular Drugs and Therapy. 1997 Jun 12;11(SUPPL. 1):291-296. https://doi.org/10.1023/A:1007748131847
Bristow, Michael R. ; Abraham, William T. ; Yoshikawa, Tsutomu ; White, Michel ; Hattler, Brack G. ; Crisman, Thomas S. ; Lowes, Brian D. ; Robertson, A. D. ; Larrabee, Patti ; Gilbert, Edward M. / Second- and third-generation beta-blocking drugs in chronic heart failure. In: Cardiovascular Drugs and Therapy. 1997 ; Vol. 11, No. SUPPL. 1. pp. 291-296.
@article{2025b5e968a042df88a36cda4933852d,
title = "Second- and third-generation beta-blocking drugs in chronic heart failure",
abstract = "The left-ventricular (LV) functional, hemodynamic, and antiadrenergic effects of metoprolol, bucindolol, and carvedilol have been compared in three concurrent placebo-controlled clinical trials in patients with symptomatic idiopathic dilated cardiomyopathy. All three drugs were well tolerated, all produced at least moderate degrees of β-blockade as assessed by reduction in exercise heart rate, and all increased the left-ventricular ejection fraction. Compared with the β1-selective, second-generation compound metoprolol, the third-generation compounds bucindolol and carvedilol lowered indices of adrenergic activity and tended to improve LV function to a greater extent. In patients with chronic heart failure there may be important therapeutic response differences between second- and third-generation beta-blocking agents.",
keywords = "Antiadrenergic activity, Beta-blocking drugs, Chronic heart failure, Exercise response, Idiopathic dilated cardiomyopathy, Ischemic cardiomyopathy, Left ventricular function",
author = "Bristow, {Michael R.} and Abraham, {William T.} and Tsutomu Yoshikawa and Michel White and Hattler, {Brack G.} and Crisman, {Thomas S.} and Lowes, {Brian D.} and Robertson, {A. D.} and Patti Larrabee and Gilbert, {Edward M.}",
year = "1997",
month = "6",
day = "12",
doi = "10.1023/A:1007748131847",
language = "English (US)",
volume = "11",
pages = "291--296",
journal = "Cardiovascular Drugs and Therapy",
issn = "0920-3206",
publisher = "Kluwer Academic Publishers",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Second- and third-generation beta-blocking drugs in chronic heart failure

AU - Bristow, Michael R.

AU - Abraham, William T.

AU - Yoshikawa, Tsutomu

AU - White, Michel

AU - Hattler, Brack G.

AU - Crisman, Thomas S.

AU - Lowes, Brian D.

AU - Robertson, A. D.

AU - Larrabee, Patti

AU - Gilbert, Edward M.

PY - 1997/6/12

Y1 - 1997/6/12

N2 - The left-ventricular (LV) functional, hemodynamic, and antiadrenergic effects of metoprolol, bucindolol, and carvedilol have been compared in three concurrent placebo-controlled clinical trials in patients with symptomatic idiopathic dilated cardiomyopathy. All three drugs were well tolerated, all produced at least moderate degrees of β-blockade as assessed by reduction in exercise heart rate, and all increased the left-ventricular ejection fraction. Compared with the β1-selective, second-generation compound metoprolol, the third-generation compounds bucindolol and carvedilol lowered indices of adrenergic activity and tended to improve LV function to a greater extent. In patients with chronic heart failure there may be important therapeutic response differences between second- and third-generation beta-blocking agents.

AB - The left-ventricular (LV) functional, hemodynamic, and antiadrenergic effects of metoprolol, bucindolol, and carvedilol have been compared in three concurrent placebo-controlled clinical trials in patients with symptomatic idiopathic dilated cardiomyopathy. All three drugs were well tolerated, all produced at least moderate degrees of β-blockade as assessed by reduction in exercise heart rate, and all increased the left-ventricular ejection fraction. Compared with the β1-selective, second-generation compound metoprolol, the third-generation compounds bucindolol and carvedilol lowered indices of adrenergic activity and tended to improve LV function to a greater extent. In patients with chronic heart failure there may be important therapeutic response differences between second- and third-generation beta-blocking agents.

KW - Antiadrenergic activity

KW - Beta-blocking drugs

KW - Chronic heart failure

KW - Exercise response

KW - Idiopathic dilated cardiomyopathy

KW - Ischemic cardiomyopathy

KW - Left ventricular function

UR - http://www.scopus.com/inward/record.url?scp=8244249474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8244249474&partnerID=8YFLogxK

U2 - 10.1023/A:1007748131847

DO - 10.1023/A:1007748131847

M3 - Article

C2 - 9211023

AN - SCOPUS:8244249474

VL - 11

SP - 291

EP - 296

JO - Cardiovascular Drugs and Therapy

JF - Cardiovascular Drugs and Therapy

SN - 0920-3206

IS - SUPPL. 1

ER -